

The §112 Rejections

The Examiner has rejected 2-4 and 6 as allegedly being indefinite. Applicants respectfully traverse these rejections. Applicants believe that the term "substantially" as used in amended claim 2 and claim 6 will be readily understood as indicating basically, essentially, or for the most part. Claims 3-4 have been amended to require a 60%-90% reduction. Support for this change can be found, for example in the paragraph spanning pages 90-91 of the specification.

Applicants believe that the above amendments and discussion fully address the Examiner's concerns regarding the claim language and respectfully request that the Examiner reconsider and withdraw his rejections under §112.

The §102 and §103 Rejections


The Examiner has rejected claims 1-12 under §102 and/or §103 over Wurzner et al. (Complement Inflamm. 1991), in some instances in combination with other references. Applicants respectfully traverse these rejections. Applicants' pending claim 1 requires that the antibody be specifically targeted to the alpha chain of human complement component C5. All of applicants' other pending claims depend from claim 1 and share this limitation. As disclosed in on page 337, first column, first paragraph (continued from previous page) "both anti-C5 mabs are directed against the β chain of C5..."

Accordingly, applicants respectfully request that the Examiner reconsider and withdraw his rejections of claims 1-12 under §102 and §103.

Conclusion

Applicants respectfully request entry of the above amendments and reconsideration and allowance of claims 1-12.

Respectfully submitted,



Seth A. Fidel, Ph.D.

Reg. No. 38,449

Alexion Pharmaceuticals

25 Science Park, Suite 360

New Haven, CT 06511

(203) 776-1790

Date: August 14, 1998